RedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27.

RedHill announces top-line results from Phase III study of RHB-104 in Crohn’s Disease; cash balance improved with $25M (gross) raised at a discount; Top-line results for TALICIA® (RHB-105) – H. pylori infection expected by the end of 2018; target price reduced to NIS 2.23